Coronary heart disease and intestinal microbiota

Area of Science:

• Microbiology
• Human Physiology
• Metabolic Diseases

Background:

• The human gut microbiota plays a crucial role in health and disease.
• Factors like diet and medication can alter the gut microbiome.
• Advances in sequencing technology enable the study of gut microbiota in chronic conditions.

Purpose of the Study:

• To review current research on the gut microbiota's role in coronary heart disease (CHD).
• To identify potential preventive strategies for CHD based on gut microbiota research.
• To suggest future research directions in this field.

Main Methods:

• Literature review of recent studies on intestinal microbiota and CHD.
• Analysis of findings related to changes in microbial composition and metabolism.
• Examination of the association between specific bacterial metabolites and CHD.

Main Results:

• Studies show altered gut microbiota composition in CHD patients, with increased Bacteroidetes and Proteobacteria, and decreased Firmicutes and Fusobacteria.
• The ratio of trimethylamine (TMA) and trimethylamine N-oxide (TMAO) metabolites is linked to CHD.
• Gut microbiota alterations are associated with metabolic changes relevant to CHD.

Conclusions:

• The gut microbiota is significantly associated with coronary heart disease.
• Metabolites like TMA and TMAO produced by gut bacteria are potential biomarkers for CHD.
• Further research into the gut microbiota may reveal novel preventive strategies for CHD.